Avastin (Bevacizumab) Market Report 2026

Avastin (Bevacizumab) Market Overview

• The Avastin (Bevacizumab) market growth in the historic period has been driven by clinical validation of vegf inhibition, rising global cancer burden • Market expansion is supported by growth of bevacizumab biosimilars, expanding oncology patient pool • Growth Driver: Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market • Market Trend: Biosimilar Expansion Intensifying Competition And Improving Affordability In Bevacizumab-Based Oncology Therapies • North America was the largest region in 2025.

What Is Covered Under Avastin (Bevacizumab) Market?

Avastin (bevacizumab) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis, the formation of new blood vessels that supply tumors with oxygen and nutrients. It is used in combination with chemotherapy to treat various cancers, including colorectal, lung, kidney, and glioblastoma. The main dosages of avastin (bevacizumab) are 100 Mg, and 400 Mg. 100mg avastin (bevacizumab) is a dosage form of medication used to treat various cancers by inhibiting the growth of blood vessels that supply tumors. It has various applications in non-squamous non-small cell lung cancer, recurrent glioblastoma, cervical cancer, colorectal cell cancer, ovarian cancer, proliferative diabetic retinopathy, malignant glioma, neurofibromatosis, pancreatic cancer, and others. These are distributed through direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others and utilized by end users such as hospitals, cancer supportive centers, home healthcare, academic and research institutes, and others.

What Is The Avastin (Bevacizumab) Market Growth Forecast?

The avastin (bevacizumab) market size is expected to see strong growth in the next few years. It will grow to $11.27 million in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growth of bevacizumab biosimilars, expanding oncology patient pool, increased use in emerging markets, demand for cost effective biologics, combination regimen optimization. Major trends in the forecast period include continued use of anti-angiogenic cancer therapies, expansion of avastin use across multiple cancer types, growing combination therapy with chemotherapy, rising adoption in ophthalmic indications, increased focus on biosimilar competition.

What Are The Drivers Of The Avastin (Bevacizumab) Market?

The increasing cancer prevalence is expected to propel the growth of the avastin (bevacizumab) market going forward. Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The prevalence of cancer is increasing due to factors such as aging populations, lifestyle changes, and improved detection methods. Avastin treats cancer by inhibiting VEGF, blocking the growth of blood vessels that supply oxygen and nutrients to tumors, effectively starving them. For instance, in August 2024, according to the Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer, this figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing cancer prevalence is driving the growth of the avastin (bevacizumab) industry. Rising healthcare expenditure is expected to propel the growth of the avastin (bevacizumab) market going forward. Healthcare expenditure refers to the total amount spent on health care goods and services, including personal health care, preventive services, and public health activities, aimed at improving health outcomes within a specific period. The rising healthcare expenditure is due to an aging population, chronic diseases, advanced medical technology, high drug prices, inefficient payment models, and increased demand for services. Healthcare expenditure benefits Avastin (bevacizumab) by increasing access to the drug through insurance coverage, supporting its market growth and broader patient use. For instance, in May 2024, according to a report published by Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Therefore, the rising healthcare expenditure is driving the avastin (bevacizumab) industry.

Key Players In The Global Avastin (Bevacizumab) Market

Major companies operating in the avastin (bevacizumab) market are Roche Holding AG

Global Avastin (Bevacizumab) Market Trends and Insights

Major companies operating in the Avastin (bevacizumab) market are focusing on biosimilar proliferation, such as high profile bevacizumab biosimilars, to gain a competitive advantage. Biosimilar proliferation refers to the rapid increase in the number and availability of biosimilar drugs in the market. For instance, in December 2023, Bio Thera Solutions, a China based biopharmaceutical company, received FDA approval for Avzivi (bevacizumab tnjn), a biosimilar to Avastin, featuring equivalent efficacy, safety, and immunogenicity as the reference product. In July 2024, the European Medicines Agency (EMA) also approved BAT1706 / Avzivi for multiple oncology indications. These developments are driving greater affordability and patient access. However, they also intensify pricing pressure on the originator, challenge market share, and demand robust manufacturing capacity for new entrants.

What Defines the Avastin (Bevacizumab) Market?

The avastin (bevacizumab) market consists of sales of intravenous (iv) formulations, and bevacizumab injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Avastin (Bevacizumab) Market Report 2026?

The avastin (bevacizumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the avastin (bevacizumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.